

**Anti-CD19 Reference Antibody (tafasitamab)
Recombinant Antibody
Catalog # APR10135****Specification**

Anti-CD19 Reference Antibody (tafasitamab) - Product Information

Application	FC, E, FTA
Primary Accession	P15391
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	147.42 KDa

Anti-CD19 Reference Antibody (tafasitamab) - Additional Information**Target/Specificity**
CD19**Endotoxin**
< 0.001EU/ µg, determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in 100mM Pro-Ac, 20mM Arg, pH5.0, without preservative. This antibody is purified through a protein A column.**Anti-CD19 Reference Antibody (tafasitamab) - Protein Information****Name** CD19**Function**
Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes (PubMed: [29523808](http://www.uniprot.org/citations/29523808)). Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed: [1373518](http://www.uniprot.org/citations/1373518), PubMed: [16672701](http://www.uniprot.org/citations/16672701), PubMed: [2463100](http://www.uniprot.org/citations/2463100)). Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca²⁺ stores (PubMed: [12387743](http://www.uniprot.org/citations/12387743), PubMed: [16672701](http://www.uniprot.org/citations/16672701), PubMed: [9317126](http://www.uniprot.org/citations/9317126), PubMed: [9382888](http://www.uniprot.org/citations/9382888)). Is not required

for early steps during B cell differentiation in the blood marrow (PubMed:9317126). Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:1373518, PubMed:2463100). Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:12387743, PubMed:16672701, PubMed:9317126).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Membrane raft
{ECO:0000250|UniProtKB:P25918}; Single-pass type I membrane protein
{ECO:0000250|UniProtKB:P25918}

Tissue Location


Detected on marginal zone and germinal center B cells in lymph nodes (PubMed:2463100).
Detected on blood B cells (at protein level) (PubMed:16672701, PubMed:2463100)

Anti-CD19 Reference Antibody (tafasitamab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CD19 Reference Antibody (tafasitamab) - Images




Anti-CD19 Reference Antibody (tafasitamab) on SDS-PAGE under reducing (R) condition. The gel


was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CD19 Reference Antibody (tafasitamab) is more than 98.59% ,determined by SEC-HPLC.



Immobilized human CD19 (20 291) Protein, His Tag at 2 µg/mL can bind Anti-CD19 Reference Antibody (tafasitamab) EC₅₀=0.0904 µg/mL



Human CD19 HEK293 cells were stained with Anti-CD19 Reference Antibody (tafasitamab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC₁₉₀=0.085 µg/mL